DHES0815A, a novel antibody-drug conjugate targeting HER2/neu, is highly active against uterine serous carcinomas in vitro and in vivo

•HER2/neu overexpressing USC cell lines are highly sensitive to DHES0815A in vitro.•DHES0815A targets HER2/neu positive cells without collateral damage to surrounding cells as seen by the bystander effect.•DHES0815A causes growth-inhibition and increased survival in HER2/neu overexpressing xenografts.